In a historic announcement on November 10, 2025, the FDA (U.S. Food and Drug Administration) released a decision that could transform the perception and use of Hormone Replacement Therapy (HRT) in the treatment of menopause. U.S. Food and Drug Administration+1

In our practice, we have been recommending various therapies, such as the use of hormone replacement therapy, for years.

Finally, something decent is published that directly helps the health of women today!

The U.S. Food and Drug Administration (FDA), in a regulatory action described as a pivotal moment for women’s health, took steps in November 2025 to remove general “black box” warnings (Boxed Warnings) from Menopausal Hormone Therapy (MHT) products. This decision is a profound regulatory adjustment intended to correct the widespread misinterpretation of risks associated with MHT since the early 2000s.

The ultimate goal of this policy is to restore evidence-based medicine and empower women and their physicians to make decisions based on contemporary scientific data, rather than historical fear.

The End of the “Fear Machine”

Regulatory leaders described the two-decade perpetuation of these warnings as a “fear machine” and “medical groupthink” that led to an “American tragedy.” Specifically, the FDA requested the removal of references to the following risks from the Boxed Warning section for most MHT products:

• Cardiovascular diseases (including myocardial infarction, stroke, and venous thromboembolism).

• Breast cancer.

• Probable dementia (for women aged 65 or older).

The justification for this reversal lies in the fact that the warnings were based on the results of the Women’s Health Initiative (WHI) trial from the 2000s, where the patient group had an average age of 63 and used formulations that are no longer today’s gold standard.

Institutionalization of the “Window of Opportunity”

The scientific basis for this regulatory correction is the Timing Hypothesis. Re-analysis of WHI subgroups has shown that for women starting MHT within the “Window of Opportunity” (generally before age 60 or within 10 years of the onset of menopause), the balance of benefits significantly outweighs the risks.

The new regulatory guidelines include two fundamental changes that transform the prescribing philosophy:

1. Removal of dose/duration restrictions: The mandatory recommendation to use MHT at the “lowest effective dose for the shortest duration” has been eliminated. This allows physicians to pursue individualized and potentially long-term therapeutic strategies for symptom relief and chronic disease prevention.

2. New initiation guidance: Language is incorporated advising physicians to consider starting systemic MHT in women under 60 or within 10 years of the onset of menopause.

Impact on Longevity and Chronic Health:

Accumulated evidence demonstrates that, for the appropriate cohort, MHT offers significant benefits that justify the removal of restrictive warnings:

• Mortality and Cardiac Risk: Women who start MHT early see a reduction in all-cause mortality and potentially a 50% reduction in the risk of heart attack.

• Cognitive Health: Contrary to the previous warning, starting MHT within the window of opportunity is associated with neurological benefits, including a 35% reduction in the risk of Alzheimer’s disease and a 64% reduction in overall cognitive decline.

• Bone Health: MHT offers a fracture reduction of up to 60%.

What other colleagues in the profession should know

While general warnings were removed, the agency demonstrated regulatory precision by maintaining the boxed warning for endometrial cancer in systemic products containing only estrogens—a precautionary measure based on known biological mechanisms.

The removal of black box warnings demands a more nuanced and detailed conversation between patient and physician. Detailed risks (especially VTE and breast cancer) are retained in the Warnings and Precautions section of the label. It is essential to focus on:

• Treatment Personalization: Physicians must differentiate between absolute contraindications and manageable risks, considering the patient’s age, time elapsed since menopause, and route of administration (oral vs. transdermal). If in doubt, refer to professionals more specialized or trained in the use of hormone replacement therapy.

• Absolute Contraindications: Labeling changes do not override the strict contraindication of systemic MHT for individuals with a history of estrogen-sensitive cancers, such as hormone receptor-positive breast cancer (however, it allows us to offer hormonal treatments with local effects without systemic absorption).

• Continuous Education: This regulatory environment will increase the demand for healthcare providers specialized in contemporary MHT protocols.

This FDA initiative is not just a label change, but a validation of MHT’s role as a crucial intervention for women’s health and longevity, requiring the entire medical community to catch up with the latest science.

In summary: The FDA’s withdrawal of the black box represents a significant advancement in women’s health. It is not about promoting the indiscriminate use of hormone therapy, but about providing more information, transparently and based on science, so that medical decisions are not dominated by fear, but by personalized assessment.

---

Bibliographic References:

1. HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy, https://www.fda.gov/news-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy

2. FDA Requests Labeling Changes Related to Safety Information to …, https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-labeling-changes-related-safety-information-clarify-benefitrisk-considerations

3. FDA Updates Menopausal Hormone Therapy Labels – Hippo Education, https://home.hippoed.com/blog/fda-updates-menopausal-hormone-therapy-labels-hippo-education

4. FDA ending ‘black box’ warning for hormone replacement therapy for women, https://www.medicaleconomics.com/view/fda-ending-black-box-warning-for-hormone-replacement-therapy-for-women

5. FDA to Remove Black Box Warnings on Hormone Replacement Therapy, https://www.healthline.com/health-news/hormone-replacement-therapy-fda-removes-black-box-warnings

6. FDA Direct: Removing Black Box Warnings for HRT (Part 2/2), https://www.fda.gov/news-events/fda-direct-podcast/fda-direct-removing-black-box-warnings-hrt-part-22

7. FDA chief says warning labels deterred women from using menopause hormone therapy: “It’s an American tragedy” – CBS News, https://www.cbsnews.com/news/fda-hormone-therapy-marty-makary-interview/

8. FDA to Remove Black Box Warnings From HRT, Debate Ensues – AJMC, https://www.ajmc.com/view/fda-to-remove-black-box-warnings-from-hrt-debate-ensues

9. FACT SHEET: FDA Initiates Removal of “Black Box” Warnings from …, https://www.hhs.gov/press-room/fact-sheet-fda-initiates-removal-of-black-box-warnings-from-menopausal-hormone-replacement-therapy-products.html

10. NBCC Statement on FDA Hormone Replacement Therapy (HRT) Black Box Warning Removal – National Breast Cancer Coalition, https://www.stopbreastcancer.org/nbcc-statement-fda-hrt-black-box/

11. Menopause: Medicines to Help You – FDA, https://www.fda.gov/consumers/free-publications-women/menopause-medicines-help-you

12. PREMARIN® (conjugated estrogens) Boxed Warning | Pfizer Medical – US, https://www.pfizermedical.com/premarin/boxed-warning

13. FDA initiates removal of boxed warnings, requests updated labeling for menopausal hormone therapy | Contemporary OB/GYN, https://www.contemporaryobgyn.net/view/fda-initiates-removal-of-boxed-warnings-from-hormone-therapy-for-menopause

14. FDA removes warning label on HRT for menopause: 5 experts explain, https://www.medicalnewstoday.com/articles/fda-black-box-warnings-hormone-replacement-therapy-menopause-explainer

15. Boxed Warnings on U.S. Food and Drug Administration–Approved Estrogen and Testosterone Products – The Clinical Utility of Compounded Bioidentical Hormone Therapy – NCBI, https://www.ncbi.nlm.nih.gov/books/NBK562883/

16. This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020216s091lbl.pdf

17. Women’s Health Initiative (WHI) – NHLBI – NIH, https://www.nhlbi.nih.gov/science/womens-health-initiative-whi

18. FDA Removes Black Box Warning on Hormone Therapy – Time Magazine, https://time.com/7332940/fda-estrogen-menopause-black-box-warning/

19. WHI responds to FDA removal of black box warning on hormonal therapies, https://www.whi.org/md/news/whi-fda-hrt-warning

20. FDA rolls back warning labels on HRT products for menopause – Fierce Healthcare, https://www.fiercehealthcare.com/regulatory/fda-rolls-back-warning-labels-hrt-products-menopause

21. Hormone Replacement Therapy (HRT) and Breast Cancer Risk, https://www.breastcancer.org/risk/risk-factors/using-hormone-replacement-therapy

22. Hormone Replacement Therapy (HRT) for Menopause – Cleveland Clinic, https://my.clevelandclinic.org/health/treatments/15245-hormone-therapy-for-menopause-symptoms

23. ASCO Statement: HHS Revision of Black Box Warning for Hormone Replacement Therapy and its Implications for Cancer Care, https://www.asco.org/news-initiatives/policy-news-analysis/statement-HHS-revision-black-box-warning

24. Tamoxifen – StatPearls – NCBI Bookshelf – NIH, https://www.ncbi.nlm.nih.gov/books/NBK532905/

25. Counseling Male Patients on Testosterone Replacement Therapy With Efficacy and Safety in Mind – U.S. Pharmacist, https://www.uspharmacist.com/article/counseling-male-patients-on-testosterone-replacement-therapy

26. Yaz and Other Oral Contraceptives Will Carry a New Warning Label, https://womensmentalhealth.org/posts/yaz-and-other-oral-contraceptives-will-carry-a-new-warning-label/